Fennec Pharmaceuticals Stock Performance
| FRX Stock | CAD 10.63 0.00 0.00% |
The firm shows a Beta (market volatility) of -1.01, which means a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Fennec Pharmaceuticals are expected to decrease slowly. On the other hand, during market turmoil, Fennec Pharmaceuticals is expected to outperform it slightly. At this point, Fennec Pharmaceuticals has a negative expected return of -0.28%. Please make sure to confirm Fennec Pharmaceuticals' variance, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Fennec Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Fennec Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:3 | Last Split Date 2014-09-05 |
1 | Can Fennec Pharmaceuticals Inc. stock maintain growth trajectory - Market Risk Summary Technical Buy Zone Confirmations - newser.com | 10/23/2025 |
2 | Will Fennec Pharmaceuticals Inc. stock benefit from Fed rate cuts - Quarterly Portfolio Report Expert Curated Trade Setups - newser.com | 11/11/2025 |
3 | Fennec Pharmaceuticals Sells Shares To Raise 35 Million - Finimize | 11/14/2025 |
4 | Fennec Pharmaceuticals Announces Underwriting Agreement for Share Offering - TipRanks | 11/17/2025 |
5 | Fennec Pharmaceuticals Closes 5M Private Offering in Canada - MSN | 11/20/2025 |
6 | Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - Yahoo Finance | 11/26/2025 |
7 | Fennec Pharmaceuticals Stock Price Passes Below Fifty Day Moving Average - Heres What Happened - MarketBeat | 12/03/2025 |
8 | Fennec Pharma announces City of Hope PEDMARK trial in metastatic testicular tumors FENC Stock News - Stock Titan | 12/09/2025 |
9 | Risk-Controlled Trading Report - news.stocktradersdaily.com | 12/12/2025 |
10 | Is Fennec Pharmaceuticals Inc. stock cheap at current valuation - 2025 Geopolitical Influence Reliable Intraday Trade Plans - ulpravda.ru | 12/19/2025 |
Fennec |
Fennec Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,299 in Fennec Pharmaceuticals on September 30, 2025 and sell it today you would lose (236.00) from holding Fennec Pharmaceuticals or give up 18.17% of portfolio value over 90 days. Fennec Pharmaceuticals is producing return of less than zero assuming 3.0026% volatility of returns over the 90 days investment horizon. Simply put, 26% of all stocks have less volatile historical return distribution than Fennec Pharmaceuticals, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Fennec Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fennec Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fennec Pharmaceuticals, and traders can use it to determine the average amount a Fennec Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0928
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FRX |
Estimated Market Risk
| 3.0 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.28 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fennec Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fennec Pharmaceuticals by adding Fennec Pharmaceuticals to a well-diversified portfolio.
Fennec Pharmaceuticals Fundamentals Growth
Fennec Stock prices reflect investors' perceptions of the future prospects and financial health of Fennec Pharmaceuticals, and Fennec Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fennec Stock performance.
| Return On Equity | -10.06 | ||||
| Return On Asset | -0.0539 | ||||
| Profit Margin | (0.18) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 359.53 M | ||||
| Shares Outstanding | 33.48 M | ||||
| Price To Earning | (42.07) X | ||||
| Price To Book | 57.98 X | ||||
| Price To Sales | 9.18 X | ||||
| Revenue | 47.54 M | ||||
| Gross Profit | 36.12 M | ||||
| EBITDA | 4.8 M | ||||
| Net Income | (436 K) | ||||
| Cash And Equivalents | 24.61 M | ||||
| Cash Per Share | 0.88 X | ||||
| Total Debt | 19.34 M | ||||
| Current Ratio | 12.96 X | ||||
| Book Value Per Share | (0.22) X | ||||
| Cash Flow From Operations | 26.98 M | ||||
| Earnings Per Share | (0.36) X | ||||
| Market Capitalization | 355.93 M | ||||
| Total Asset | 44.95 M | ||||
| Retained Earnings | (219.68 M) | ||||
| Working Capital | 37.2 M | ||||
About Fennec Pharmaceuticals Performance
By examining Fennec Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Fennec Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Fennec Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 121.51 | 115.44 | |
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | 0.08 | 0.08 |
Things to note about Fennec Pharmaceuticals performance evaluation
Checking the ongoing alerts about Fennec Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fennec Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fennec Pharmaceuticals generated a negative expected return over the last 90 days | |
| Fennec Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the revenue of 47.54 M. Net Loss for the year was (436 K) with profit before overhead, payroll, taxes, and interest of 36.12 M. | |
| About 13.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Is Fennec Pharmaceuticals Inc. stock cheap at current valuation - 2025 Geopolitical Influence Reliable Intraday Trade Plans - ulpravda.ru |
- Analyzing Fennec Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fennec Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Fennec Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fennec Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fennec Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fennec Pharmaceuticals' stock. These opinions can provide insight into Fennec Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. To learn how to invest in Fennec Stock, please use our How to Invest in Fennec Pharmaceuticals guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.